课题基金 / 基金详情

PREDICTION OF ADVERSE EFFECTS OF AMIODARONE BY SIGNAL AVERAGING IN HCM PATIENTS

PREDICTION OF ADVERSE EFFECTS OF AMIODARONE BY SIGNAL AVERAGING IN HCM PATIENTS
通过 HCM 患者的信号平均来预测胺碘酮的不良反应
批准号:
3920190
负责人:
L FANANAPAZIR
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

L FANANAPAZIR的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Analysis of the terminal portion of the QRS of the ECG and detection of late potential (LP) by signal averaging (SAE) is a noninvasive method for identifying patients who are prone to develop ventricular tachycardia (VT) and are therefore at risk for sudden cardiac death. We have earlier shown that there was a and correlation between the presence of LP and inducibility of VT in patients with hypertrophic cardiomyopathy (HCM). Amiodarone is a patient antiarrhythmic drug. The purpose of the present investigation was to determine whether changes in SAE predicted efficacy and proarrhythmic potential in 14 HCM patients treated with amiodarone. Amiodarone increased the incidence of LP. This was associated with the greater ease with which VT was induced during programmed electrical stimulation. Thus SAE may identify HCM patients in whom amiodarone is proarrhythmic and may be at increased risk for sudden cardiac death.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INDUCTION OF MALIGNANT VENTRICULAR TACHYCARDIA ON AMIODARONE IN HCM PATIENTS
CENTRAL CORE DISEASE IN HYPERTROPHIC CARDIOMYOPATHY
INHERITED CARDIAC DISEASES--HYPERTROPHIC CARDIOMYOPATHY
MANAGEMENT OF SYMPTOMS AND ARRHYTHMIAS IN HYPERTROPHIC CARDIOMYOPATHY